ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
Launched by PFIZER · Dec 12, 2008
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Sampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
- Exclusion Criteria:
- • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Chengdu, Sichuan, China
Daegu Si, , Korea, Republic Of
Guangzhou, Guangdong, China
Shanghai, , China
Quezon City, , Philippines
Suwon, , Korea, Republic Of
Cochin, Kerala, India
Daejeon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Mumbai, Maharashtra, India
Daegu, , Korea, Republic Of
Seongnam Si, Gyeonggi Do, Korea, Republic Of
Marikina City, , Philippines
Davao City, , Philippines
Cheonan Si, Chungcheongnam Do, Korea, Republic Of
Wuhan, Hubei, China
Beijing, Beijing, China
Shenzhen, Guangdong, China
Changsha, Hunan, China
Nanjing, Jiangsu, China
Suzhou, Jiangsu, China
Shenyang, Liaoning, China
Xi'an, Shaanxi, China
Xian, Shaanxi, China
Taiyuan, Shanxi, China
Tianjin, Tianjin, China
Nanning, , China
Shijiazhuang, , China
Hyderabad, Andhra Pradesh, India
New Delhi, Delhi, India
Ahmadabad, Gujarat, India
Tthiruvananthapuram, Kerala, India
Daryaganj, New Delhi, India
Delhi,, New Delhi, India
Delhi, New Delhi, India
Coimbatore, Tamil Nadu, India
Chennai, , India
Goyang Si, Gyeonggi Do, Korea, Republic Of
Suwon Si, Gyeonggi Do, Korea, Republic Of
Yangsan Si, Gyeongnam, Korea, Republic Of
Iksan Si, Jeollabuk Do, Korea, Republic Of
Incheon Si, , Korea, Republic Of
San Juan, Batangas, Philippines
Batac, Ilocos Norte, Philippines
San Fernando City, La Union, Philippines
Angeles City, Pampanga, Philippines
Urdaneta City, Pangasinan, Philippines
Tarlac City, Tarlac, Philippines
Pasay City, , Philippines
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials